Send to

Choose Destination
See comment in PubMed Commons below
Curr Neuropharmacol. 2009 Dec;7(4):269-75. doi: 10.2174/157015909790031157.

Mmp-9, a potential target for cerebral ischemic treatment.

Author information

Department of Pharmacology, School of Pharmaceutical Sciences, Shandong University, No. 44 WenHuaXi Road, Jinan 250012, P.R. China.


Matrix metalloproteinase-9 (MMP-9) which is a member of matrix metalloproteinases family that normally remodel the extracellular matrix, has been shown to play an important role in both animal models of cerebral ischemia and human stroke. The expression of MMP-9 is elevated after cerebral ischemia which is involved in accelerating matrix degradation, disrupting the blood-brain barrier, increasing the infarct size and relating to hemorrhagic transformation. Recently, many drugs, such as tetracycline derivatives, cyclooxygenase inhibitors, ACEI inhibitors and AT1 receptor blockers, etc., have been found to attenuate the elevated expression levels of MMP-9 after ischemia and to reduce the damage of cerebral ischemic. This article reviews the physiological features of MMP-9 and its important role in the genesis, propagation, and therapeutics of cerebral ischemic diseases.


Matrix metalloproteinase-9 (MMP-9); cerebral ischemia; regulation; therapeutical target.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center